



Press release
2 March, 2020

Kringle Pharma Successfully Raises 950 Million Japanese Yen to Advance Clinical Development of Recombinant Human HGF for the Treatment of Acute Spinal Cord Injury

Kringle Pharma, Inc. (Head office located in Ibaraki, Osaka; President & CEO, Kiichi Adachi; “KRINGLE”) announces that the company has successfully raised funds amounting to 950 million Japanese yen (approximately \$8.7 million US dollars). The companies participating in this funding round in KRINGLE include existing shareholders (*Nippon Zenyaku Kogyo Co., Ltd.*, *Keio Innovation Initiative, Inc.*, *DBJ Capital Co., Ltd.*, and *Tohoku University Venture Partners Co., Ltd.*) as well as new investors such as *Toho Holdings Co., Ltd.*, *CEJ Capital Inc.*, *M3 Inc.*, *POC Clinical Research Inc.*

Hepatocyte growth factor (HGF) is considered an intrinsic repair and regeneration factor for various tissues and organs, and is thought to have significant potential as an innovative medicine for many intractable diseases. KRINGLE has been deeply engaged in the clinical development of recombinant human HGF (rhHGF) for acute spinal cord injury and amyotrophic lateral sclerosis (ALS). Funds raised by this capital increase will be used for the preparation and initiation of a seminal Phase III clinical study in acute spinal cord injury, GMP production of rhHGF and its process validation in anticipation of a new drug application in Japan.

About Kringle Pharma, Inc. <https://www.kringle-pharma.com/en/>

Kringle Pharma is a clinical-stage biopharmaceutical company established in December 2001 to develop novel biologics based on HGF. Currently, Kringle’s clinical programs with rhHGF are: 1) Phase I/II DBT in acute spinal cord injury (completed), 2) investigator-initiated Phase II DBT in ALS (ongoing), 3) Phase I in acute kidney injury (completed), and 4) investigator-initiated Phase I/II in vocal fold scar (completed). Kringle’s mission is to contribute to societal and global health through the continued research, development and commercialization of HGF for patients suffering from incurable diseases.

For more information, please contact:

Yutaka Matsuura, C.P.A.

Director of Corporate Planning Management, Member of the Board

Kringle Pharma, Inc.

☎ +81-72-641-8739

✉ kpinfo@kringle-pharma.com